NASHUA, N.H. and Miami, Fla., 9 November 2017 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that clinical research comparing use of the company’s Xoft® Electronic Brachytherapy (eBx®) System® to Mohs surgery in the treatment of early-stage non-melanoma skin cancer (NMSC) has been selected “Best of ASTRO 2017.” The “Best of ASTRO” distinction is reserved for the most relevant and highly influential abstracts presented at the 2017 Annual Meeting. The study revealed no statistically significant difference in recurrence of cancer at a mean follow-up of 3.4 years when comparing both forms of treatment. Key findings from the data will be presented at the Best of ASTRO meeting on Nov. 10-11 at the Loews Miami Beach Hotel in Miami, Fla.

“We are honored that ASTRO, the world’s leading radiation oncology society, has recognized the unique, clinical value of our innovative NMSC treatment,” said Ken Ferry, CEO of iCAD. “This acknowledgment further validates the promise of our technology and the significant benefits eBx continues to offer both patients and providers globally.”

In an oral presentation at the 2017 Annual Meeting, Dr. Rakesh Patel, radiation oncologist at Precision Cancer Specialists and lead investigator of the clinical study, presented results of a matched-pair cohort study of 369 early-stage NMSC patients treated with either the Xoft System or Mohs micrographic surgery, known as the gold standard NMSC treatment. Originally published in the peer-reviewed Journal of Contemporary Brachytherapy, the study found that rates of recurrence of cancer in patients treated with eBx or Mohs micrographic surgery were virtually identical. At a mean follow up of 3.4 years, 99.5 percent of eBx patients and 100 percent of Mohs surgery patients remained recurrence free. Further, overall incidence of toxicity was similar in both treatment groups and physician-rated cosmetic outcomes were either “excellent” or “good” in 97.6 percent of eBx-treated lesions, compared to 95.7 percent of Mohs surgery-treated lesions.

“Best of ASTRO recognition empowers physicians with access to meaningful and leading-edge clinical research,” said Dr. Patel. “This important study provides further clinical evidence that eBx is an effective, non-invasive treatment option that achieves similar low rates of recurrence with excellent cosmetic outcomes as compared to Mohs surgery for NMSC patients.”

The Xoft System is FDA-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including NMSC, early-stage breast cancer and gynecological cancers. The technology features a miniaturized, low-energy X-ray source that delivers a precise dose of targeted, isotope-free radiation directly to the lesion, reducing the risk of damage to surrounding healthy tissue.

About iCAD, Inc.

Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com